주요 급성 감염의 정맥 주사 대 경구 치료
응급실 주요 급성감염의 정맥주사 vs 경구치료
Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.
Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Patients admitted to the hospital with infections are often treated with intravenous antibiotics. The rationale for using intravenous antibiotics includes eliminating the risk of reduced absorption, achieving higher serum concentrations, and the fact that many broad-spectrum antibiotics (such as cephalosporins and carbapenems) are not available in oral form. However, intravenous antibiotics also have drawbacks, such as the risk of catheter-related infections, challenges in home-based treatment, and difficulty switching to oral antibiotics unless microbiological results are definitively positive. Prolonged hospital stays associated with intravenous antibiotic treatment lead to economic burdens, increased risk of hospital-acquired infections, and significant functional decline, especially in older patients.
In recent decades, many studies have explored the possibility of fully or partially replacing intravenous antibiotics with oral antibiotics for certain infections.
In this study, the investigators will examine the safety and efficacy of primarily oral antibiotic regimens in patients with confirmed or suspected infections admitted to the emergency department. The study is an open-label, prospective, randomized controlled trial. Participants will be randomly assigned to receive either standard intravenous antibiotic treatment according to Danish guidelines or oral antibiotic treatment based on tailored recommendations developed by microbiologists and infectious disease specialists at participating sites, in accordance with local guidelines.
The study has two primary outcomes: 1) Efficacy-measured as the number of days alive outside the hospital within 30 days after randomization, and 2) Safety-measured by mortality or the need for vasopressors within 30 days after randomization. A total of 2640 patients will be needed to address both primary outcomes.
Aim: The trial aims to investigate the safety and efficacy of oral antibiotic administration compared to intravenous antibiotic administration in patients referred to the emergency department with suspected or diagnosed bacterial pneumonia, urinary tract infection and cellulitis.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Helene Skjøt-Arkil
- 전화번호: +45 79971113
- 이메일: hsa@rsyd.dk
연구 연락처 백업
- 이름: Mariana Bichuette Cartuliares
- 전화번호: +45 79971113
- 이메일: mbc@rsyd.dk
연구 장소
-
-
-
Copenhagen, 덴마크, 2400
- 모병
- Bispebjerg and Frederiksberg Hospital
-
연락하다:
- Frederik Neess Engsig
-
Copenhagen, 덴마크
- 모병
- Nordsjællands Hospital
-
연락하다:
- Jon Gitz Holler
-
Esbjerg, 덴마크, 6700
- 모병
- Esbjerg and Grindsted Sygehus
-
연락하다:
- Peter Biesenbach
-
Herlev, 덴마크, 2730
- 모병
- Herlev and Gentofte Hospital
-
연락하다:
- Kasper Iversen
- 이메일: kasper.karmark.iversen@regionh.dk
-
Hvidovre, 덴마크, 2650
- 모병
- Amager and Hvidovre Hospital
-
연락하다:
- Thomas Benfield
- 이메일: thomas.lars.benfield@regionh.dk
-
Kolding, 덴마크, 6000
- 모병
- Sygehus Lillebælt
-
연락하다:
- Lone Wulff Madsen
-
-
Southern Denmark
-
Aabenraa, Southern Denmark, 덴마크, 6200
- 모병
- Sygehus Sønderjylland
-
연락하다:
- 이메일: CBM1@rsyd.dk
-
Sønderborg, Southern Denmark, 덴마크, 6400
- 모병
- Sygehus Sønderjylland
-
연락하다:
- Christian Backer Mogensen
- 전화번호: 0045 79970000
- 이메일: CBM1@rsyd.dk
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician
- Planned or initiated intravenous antibiotic treatment
Exclusion Criteria:
- if received more than two doses of intravenous antibiotics;
- systolic blood pressure <90 mmHg;
- nausea and/or vomiting in more than one short-term instance during the last 2 days;
- suspected significantly reduced gastrointestinal absorption;
- confirmed plasma-lactate > 2;
- pregnant or nursing;
- unable to give informed consent;
- severe immunodeficiency;
- urgent vital treatment needed.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
간섭 없음: Standard Care
Standard intravenous treatment in accordance with local or national procedures |
|
|
활성 비교기: Oral treatment
Oral treatment |
Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Days alive outside hospital (Efficacy)
기간: From randomization date to 30 days
|
The number of days the patients are alive outside hospital within 30 days after randomization |
From randomization date to 30 days
|
|
Number of patients requiring treatment with vasopressors
기간: From date of randomization to 30 days
|
Number of patients that die or number of patients that require treatment with vasopressors within 30 days after randomization |
From date of randomization to 30 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Length of hospital stay
기간: From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months
|
Duration of hospital length of stay in days |
From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months
|
|
Inhospital mortality
기간: From date of randomization until date of death in hospital from any cause, assessed up to 6 months
|
The number of death measured inhospital before discharge |
From date of randomization until date of death in hospital from any cause, assessed up to 6 months
|
|
30-days mortality
기간: up to 30 days from baseline (randomization date)
|
The number of death within 30 days |
up to 30 days from baseline (randomization date)
|
|
90-days mortality
기간: Up to 90 days from baseline (randomization date)
|
The number of death within 90 days |
Up to 90 days from baseline (randomization date)
|
|
One-year mortality
기간: Up to one-year from baseline (randomization date)
|
The number of death within one-year |
Up to one-year from baseline (randomization date)
|
|
Five-year mortality
기간: Up to five-years from baseline (randomization date)
|
The number of death within five-years |
Up to five-years from baseline (randomization date)
|
|
Discharge within 24 hours
기간: Up to 24 hours after rom baseline (randomization date)
|
The number of patients discharged within 24 hours |
Up to 24 hours after rom baseline (randomization date)
|
|
Readmission
기간: 30 days after discharge date
|
The number of patients readmitted to hospital |
30 days after discharge date
|
|
Intensive care admission
기간: From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months
|
Number of patients admitted to intensive care during current hospital stay |
From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months
|
|
Days on antibiotic treatment within 30 days
기간: Within 30 days from randomization date
|
Number of days the patient have been treated with antibiotics |
Within 30 days from randomization date
|
|
Bacteremia
기간: Day 7 to day 30 from randomization date
|
Number of patients diagnosed with bacteremia |
Day 7 to day 30 from randomization date
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- SHS-ED-1-2024
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .